The radio programme La Tarde broadcasted by COPE has interviewed Manuel Serrano, ICREA researcher at the Institute for Research in Biomedicine (IRB Barcelona), about human aging. Serrano emphasizes that one of the basic aspects of aging is childhood health.
Scientists at CSIC sequence the genome of the gilthead seabream
The spin-off Nostrum Biodiscovery wins the 2019 Senén Vilaró Prize
Researchers at IRB Barcelona study how altered protein degradation contributes to the development of tumours
International scientists point to immunotherapy as a new approach for treating diseases related to ageing
The newspaper La Vanguardia has published two articles about the most recent work done by Joan Massagué, Director of the Sloan Kettering Institute, co-founder of the Institute for Research in Biomedicine (IRB Barcelona) and current chair of its External Advisory Board. In a study published in the journal Nature Cancer, Massagué reveals the mechanism that gives rise to metastasis.
The Preguntas Big Van section of La Vanguardia has published an article on a new joint project being done by Raúl Méndez, group leader at the Institute for Research in Biomedicine (IRB Barcelona), together with Mercedes Fernández, researchers at the Instituto de Investigaciones Biomédicas August Pi i Sunyer.
Alumni - Research Associate
«Controlling a biological process from outside is the future of chemistry and opens up promising roads for advancements in pharmacological research.»
More info on this news here.
Felice Alessio Bava
IRB Barcelona Alumni member
«We suspected that CPEB1, a protein involved in regulating mRNA translation in the cytoplasm, might also be active in the nucleus and play a role in controlling pre-mRNA processing. We discovered that it affects the alternative generation in the mature mRNA of the 3'-UTR, regions where most of the elements regulating translation in time and space are located.»
More info about this news here.
«98% of the potential therapeutic molecules against diseases of the central nervous system cannot cross the blood-brain barrier. We develop peptides with the capacity to open the doors of the barrier and act as shuttles when attached to a therapeutic molecule.»
«Our study highlights the complexity of p38 functions, both in cancer and in the maintenance of normal tissues. It shows why an inhibitor of this molecule could effectively have undesirable side effects. But these do not exclude it from being a target against cancer.»
More on this news here.
Basic information about IRB
IRB Barcelona has been awarded the "HR Excellence in Research" logo. This recognition reflects the commitment of the Institute to continuously improving its human resources policies in line with the European Charter for Researchers and the Code of Conduct for the Recruitment of Researchers. The award confirms the efforts of the Institute to ensure fair and transparent recruitment and appraisal procedures. Click here for more information.
IRB Barcelona is home to nearly 450 research, technical and support staff from 35 countries who share the common goal of contributing to the advancement of the biomedical sciences through investigator–driven research, and improving quality of life by applying advances in this field.
The convergence of biology, chemistry, and structural and computational biology is unique at IRB Barcelona and opens a strategic window to gain insight into basic molecular processes in health and disease.
Research is conducted by 23 groups organized into 5 interdisciplinary programmes. Each programme includes a diverse faculty of researchers with overlapping scientific interests. The research areas have been structured to be highly interactive, fostering multidisciplinarity by combining modern molecular biology, classical genetics, biochemistry, structural biology, bioinformatics, systems biology, advanced microscopy, and genomic and proteomic approaches.